APHA:NSD-Aphria Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 12.42

Change

0.00 (0.00)%

Market Cap

USD 3.90B

Volume

0.05B

Average Target Price

USD 13.70 (+10.28%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-17 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

N/A

USD12.55B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

N/A

USD3.93B 38.08 N/A
PCRX Pacira BioSciences, Inc

N/A

USD3.20B 25.14 65.69
TLRY Tilray, Inc

N/A

USD3.12B N/A N/A
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.77B 15.78 14.06
ENDP Endo International plc

N/A

USD1.64B N/A 9.98
SUPN Supernus Pharmaceuticals, Inc

N/A

USD1.54B 12.12 7.71
ORGO Organogenesis Holdings Inc

N/A

USD1.21B 456.50 77.95

ETFs Containing APHA

Symbol Name Weight Mer Price(Change) Market Cap
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

N/A

USD0.94B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

N/A

N/A
THCX The Cannabis ETF 0.00 % 0.70 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 79.48% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.48% 98% A+ 98% A+
Trailing 12 Months  
Capital Gain 135.67% 96% A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 135.67% 96% A 89% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -11.93% 40% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.93% 40% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 31.15% 70% C- 47% F
Risk Adjusted Return -38.30% 39% F 16% F
Market Capitalization 3.90B 96% A 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 41.54 30% F 27% F
Price/Book Ratio 2.64 67% D+ 51% F
Price / Cash Flow Ratio -29.17 89% B+ 88% B+
EV/EBITDA 454.68 4% F 3% F
Management Effectiveness  
Return on Equity -11.82% 70% C- 41% F
Return on Invested Capital -0.06% 79% C+ 46% F
Return on Assets 0.24% 75% C 48% F
Debt to Equity Ratio 22.09% 54% F 62% D-
Technical Ratios  
Short Ratio 1.90 68% D+ 60% D-
Short Percent N/A N/A N/A N/A N/A
Beta 2.64 11% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector